Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-06-14
2011-06-14
Hui, San-ming (Department: 1628)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
Reexamination Certificate
active
07960398
ABSTRACT:
The present invention relates to methods for identifying compounds useful for regulating TNF-alpha levels and/or activity. The invention also relates to methods for decreasing TNF-alpha levels and/or activity. Compounds and compositions according to this invention are useful for treating TNF-mediated diseases. The invention also relates to kits comprising the compounds and compositions herein and a tool for measuring TNF-alpha activity and/or levels.
REFERENCES:
patent: 6184210 (2001-02-01), Keana et al.
patent: 6184244 (2001-02-01), Karanewsky et al.
patent: 6187771 (2001-02-01), Karanewsky et al.
patent: 6197750 (2001-03-01), Karanewsky et al.
patent: 6214858 (2001-04-01), Lee et al.
patent: 6242422 (2001-06-01), Karanewsky et al.
patent: 6355618 (2002-03-01), Cai et al.
patent: 2003/0232846 (2003-12-01), Golec et al.
patent: WO 00/55114 (2000-09-01), None
patent: WO 00/55127 (2000-09-01), None
patent: WO 00/61542 (2000-10-01), None
patent: WO 01/05772 (2001-01-01), None
patent: WO 01/10383 (2001-02-01), None
patent: WO 01/16093 (2001-03-01), None
patent: WO 01/42216 (2001-06-01), None
patent: WO 01/72707 (2001-10-01), None
patent: WO 01/90070 (2001-11-01), None
patent: WO 01/94351 (2001-12-01), None
patent: WO 02/22611 (2002-03-01), None
patent: WO 02/42278 (2002-05-01), None
patent: WO 02/085899 (2002-10-01), None
patent: WO 02/094263 (2002-11-01), None
Aggarwalt, B.B. and Eessalu, T.E., “Induction of Receptors for Tumor Necrosis Factor-α by Interferons Is Not a Major Mechanism for Their Synergistic Cytotoxic Response,”The Journal of Biological Chemistry, 262:10000-10007 (1987).
Ausubel, F.M., et al.,Current Protocols in Molecular Biology, vol. 2, John Wiley & Sons, Inc., New York.
Cohen, R.B. and Dittrich, K.A., “Anti-TNF Therapy and Malignancy—A Critical Review,”Can J Gastroenterol, 15:376-384 (2001).
Deryckere, F., et al., “Tumor Necrosis Factor α Increases Expression of Adenovirus E3 Proteins,”Immunobiol, 193:186-192 (1995).
Levesque, A., et al., “Improved Fluorescent Bioassay for the Detection of Tumor Necrosis Factor Activity,”Journal of Immunological Methods, 178:71-76 (1995).
Liu, X-S., et al., “The Significance of Changes in Serum Tumor Necrosis Factor (TNF) Activity in Severely Burned Patients,”Burns, 20:40-44 (1994).
Ostrove, J.M. and Gifford, G.E., “Simulation of RNA Synthesis in L-929 Cells by Rabbit Tumor Necrosis Factor,”Proceedings of the Society for Experimental Biology and Medicine, 160:354-358 (1979).
Roggo, S., et al., “P2/3Oxo Azepenio Indoles: A New Class of Potent Broad Spectrum Caspase Inhibitors with in Vivo Activity in the pMCAO Model,”American Chemical Society(ACS)National Meeting in San Diego, Apr. 2001.
Roggo, S., et al., “Optimized Synthesis of a Highly Potent, Brain Penetrable Caspase Inhibitor,”American Chemical Society(ACS)National Meeting in San Diego, Apr. 2001.
Scheringa, M. and Marquet, R.L., “TNF: A Bried Review with Emphasis on its Antitumor Activity,”Biotherapy, 2:275-281 (1990).
Tracey, K.J. And Cerami, A., “Tumor Necrosis Factor: A Pleiotropic Cytokine and Therapeutic Target,”Annu. Rev. Med., 45:491-503.
Wallach, D., “Cell Death Induction by TNF: a Matter of Self Control,”TIBS, 22:107-109 (1997).
Office Action mailed May 13, 2008 in U.S. Appl. No. 10/166,437.
Keisuke et al.,“Altered Cytokine Export and Apoptosis in Mice Deficient in Interlukin-1-beta Converting Enzyme”,Science, 267(5206):2000-2003 (1995).
Randle et al, “ICE/Caspase-1 Inhibitors as novel anti-inflammatory drugs”;Expert Opinion on Investigational Drugs. England, 10(7): 1207-1209 (2001).
Diu-Hercend Anita
Golec Julian
Hercend Thierry
Lang Paul
Miller Karen
Haley Jr. James F.
Hui San-ming
Ropes & Gray LLP
Vertex Pharmaceuticals Incorporated
Xu Yang
LandOfFree
Regulation of TNF-alpha does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Regulation of TNF-alpha, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Regulation of TNF-alpha will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2623558